Bairey Merz C Noel, Gulati Martha, Wei Janet
Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vascul Pharmacol. 2023 Dec;153:107243. doi: 10.1016/j.vph.2023.107243. Epub 2023 Nov 14.
Myocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). While event rates are high enough to warrant concern, they are relatively low enough to require trials with large sample sizes and hard outcomes. Tailored therapies include common sense therapeutic lifestyle change (TLC) and optimal medical therapy (OMT) due to the high prevalence of non-obstructive CAD, however therapeutic clinical trials are needed. Currently one large outcome trial in ischemia with no obstructive coronary artery disease (INOCA) is ongoing.
随着对这种类型心肌梗死(MI)的认识日益增加,无阻塞性冠状动脉疾病的心肌梗死(MINOCA)的诊断检查、风险分层和个性化治疗正在兴起。使用先进成像技术的诊断检查可包括冠状动脉造影/血管内超声(IVUS)/光学相干断层扫描(OCT)、超声心动图和心脏磁共振成像(MRI)。与多支血管阻塞性冠状动脉疾病(CAD)相比,风险分层预示着中等风险。虽然事件发生率高到足以引起关注,但又相对低到需要进行大样本量和硬终点的试验。由于非阻塞性CAD的高患病率,个性化治疗包括常识性治疗性生活方式改变(TLC)和优化药物治疗(OMT),然而仍需要治疗性临床试验。目前,一项针对无阻塞性冠状动脉疾病(INOCA)缺血的大型结局试验正在进行中。